Experts explore current and future use of biosimilars in dermatology, gastroenterology, and rheumatology.
This is a video synopsis/summary of a panel discussion involving Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and the Winship Cancer Institute; Alice B. Gottlieb, MD, PhD, clinical professor and medical director in the Department of Dermatology at the Icahn School of Medicine at Mount Sinai; Bincy Abraham, MD, MS, professor of clinical medicine in the Academic Division of Gastroenterology and Hepatology at Houston Methodist Hospital; Jamie T. Brogan, APRN, nurse practitioner at Northwestern Medicine; and Vibeke Strand, MD, biopharmaceutical consultant and adjunct clinical professor in the Division of Immunology and Rheumatology at Stanford University School of Medicine.
The discussion focuses on the evolving landscape of biosimilars, specifically the role of adalimumab biosimilars, in dermatology, gastroenterology, and rheumatology. Gottlieb highlights the exclusive use of infliximab and rituximab biosimilars in her dermatology practice, expressing interest in upcoming adalimumab biosimilars and emphasizing the importance of interchangeability. Abraham, in gastroenterology, stresses the significance of maintaining stability for patients on adalimumab due to the potential consequences of disease flares. Strand, in rheumatology, anticipates the use of adalimumab biosimilars, emphasizing the preference for those with interchangeable designations and citing reassuring data on immunogenicity.
The panel discusses the impact of biosimilars on patient stability, with Haumschild underscoring the importance of avoiding complications or disease progression. The conversation covers the challenges of payer coverage decisions and potential switches to biosimilars. Brogan contributes insights into the auto substitution process, highlighting the need for shared decision-making and patient education.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
May 15th 2024Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Patients With MG Report Higher Azathioprine Discontinuation vs Other Immunosuppressants
May 15th 2024Survey data from over 200 patients showed that treatment discontinuation was lower for those taking mycophenolate or methotrexate than for those taking azathioprine for their myasthenia gravis (MG).
Read More